Fluoro Sialic Acid Conjugates for Therapeutic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to introduce or modify glycosylation patterns of polypeptides, especially in prokaryotic hosts, leading to differences in properties and stability of therapeutic proteins, as glycosylation is rarely achieved in these hosts, and existing methods with fluorine-substituted sugars are not practical for synthesizing fluoro sialic acid conjugates.
Innovation Solution
The use of 3-fluoro sialic acid compounds, which are reacted with sugar acceptors in the presence of sialyl transferases or trans-sialidases to form covalent conjugates without a cytosine monophosphate group, allowing for the modulation of biological properties and increased resistance to enzymatic degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glycosylation is introduced to polypeptides in eukaryotic cells, then the biological properties and stability of therapeutic polypeptides are improved, but the manufacturing complexity and cost increase due to the need for eukaryotic expression systems
Solution Approach 1:
The patent uses fluorine substitution at the 3-position of sialic acid, which fundamentally changes the chemical parameter of the glycan structure. This parameter change (introducing fluorine) provides resistance to enzymatic degradation by sialidases while maintaining the biological function, thereby improving stability without requiring complex eukaryotic expression systems
Solution Approach 2:
The patent employs sialyl transferase enzymes as intermediaries to catalyze the formation of fluoro sialic acid conjugates. These enzymes mediate the glycosylation reaction between activated fluoro sialic acid donors and polypeptide acceptors, enabling controlled modification while simplifying the manufacturing process compared to direct eukaryotic cell expression
2Duration of action of moving object
If glycosylation patterns are modified to increase half-life of therapeutic polypeptides, then the duration of action is improved, but the difficulty of synthesizing modified glycosylation structures increases
Solution Approach 1:
The patent prepares activated fluoro sialic acid donors in advance with pre-installed leaving groups (such as trifluoromethanesulfonate). This preliminary action creates ready-to-use substrates that can be directly employed in sialyl transferase-catalyzed reactions, simplifying the overall synthesis process while achieving the desired half-life extension
Solution Approach 2:
The patent divides the glycosylation modification process into separate functional components: (1) the fluoro sialic acid donor with specific leaving group, (2) the sialyl transferase enzyme, and (3) the polypeptide acceptor. This segmentation allows each component to be optimized and prepared independently, making the overall process more manageable and scalable
3Reliability
If fluorine-substituted sugars are used to resist enzymatic degradation, then the stability is improved, but the existing methods for synthesizing fluoro sialic acid conjugates are not practical
Solution Approach 1:
The patent replaces complex chemical synthesis mechanisms with enzymatic catalysis. Instead of using cumbersome chemical methods to form glycosidic bonds, the invention employs sialyl transferase enzymes to catalyze the reaction between activated fluoro sialic acid donors and polypeptide acceptors, dramatically simplifying the synthesis process while maintaining the stability benefits of fluorine substitution
Solution Approach 2:
The patent changes the activation parameter of fluoro sialic acid by using non-CMP activated forms with alternative leaving groups. This parameter change makes the substrate compatible with enzymatic catalysis while maintaining resistance to enzymatic degradation, resolving the contradiction between stability and synthesizability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of glycosylation structures with enhanced stability and pharmacokinetic properties, overcoming the limitations of previous methods by allowing the introduction of fluoro sialic acid conjugates into therapeutic moieties, improving the half-life and stability of therapeutic proteins.
Implementation Method 1
reacted with sugar acceptors in the presence of sialyl transferases or trans-sialidases to form covalent conjugates
Data Source
AI summary
Techniques to glycosylation are described, and more particularly to the production of glycosylation structures that are resistant to enzymatic degradation, thereby modulating one or more of their biological properties or those of therapeutic moieties incorporating them, and in particular to reacting activated carbohydrate substrates containing fluorine, such as 3-fluoro sialic acid compounds, with sugar acceptors to produce covalent conjugates of the sugar acceptor and one or more of the sialic acid compounds.